Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Mongolian medicine for curing lung interstitial substance fibrosis

A technology of pulmonary interstitial fibrosis and Mongolian medicine, which is applied in the field of medicine, can solve the problems of complicated treatment, unreported drugs with definite curative effect, and limited therapeutic effect

Active Publication Date: 2008-08-27
内蒙古阿迪斯蒙医药有限公司
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Western medicine mainly uses glucocorticoids and immunosuppressants for this disease, and the treatment effect is very limited, and many complications will follow, making the treatment more complicated
There is no record of this disease in the ancient literature of traditional Chinese medicine. In recent years, some research reports have referred to the disease as "shortness of breath", "cough", "lung atrophy", "lung distention" and "lung impediment", etc. No drug with definite curative effect has been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0008] Select raw materials according to the standard: 60g of wintergreen leaves, 40g of salvia miltiorrhiza, 40g of northern sea ginseng, 20g of seabuckthorn, 20g of bitter almond, 20g of licorice, and 10g of geranium. After crushing, pass through a 200-mesh sieve, and pack into capsules.

[0009] Dosage: 3-5g / time, 2-3 times / day.

[0010] Prescription principles and pharmacological analysis: The pathological damage of interstitial pneumonia is mainly inflammation of the alveolar wall in the early stage of the disease, diffuse pulmonary interstitial fibrosis in the middle stage, and fibrosis of the alveolar wall in the late stage. X-ray lung examination, especially high-resolution CT (HRCT) examination, can be found in both lung lobes, especially the lower lung lobe, showing dense and fine reticular nodules, which are relatively uniform and ill-defined, or There are cord-like lesions, grid shadows, and honeycombing. The biggest feature of this disease is: insidious onset, p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a drug, in particular to a Mongolian drug for curing the pulmonary interstitial fibrosis. The Mongolian drug is prepared by the following bulk drugs calculated according to the amounts by weight: 40 to 80 parts of leaf of Chinese ilex, 30 to 50 parts of red sange root, 30 to 50 parts of beach silvertop root, 10 to 30 parts of seabuckthorn fruit, 10 to 30 parts of bitter apricot kernel, 10 to 30 parts of licorice root and 5 to 20 parts of tabasheer. Because the experimental dosage type adopts a capsule, the drug is called compound holly capsule. A plurality of clinical experiments are verified that the compound holly capsule has the functions of clearing Badegan pathogenic heat, reducing phlegm and resolving masses, relieving asthma and activating the channels; the drug has unique therapeutic effect to the interstitial pulmonary fibrosis, and simultaneously has good therapeutic effects on the respiratory diseases, such as the wintercough, the bronchitis, the emphysema and the asthma.

Description

Technical field [0001] The invention relates to a medicine, namely a Mongolian medicine for treating pulmonary interstitial fibrosis. Background technique [0002] Idiopathic pulmonary fibrosis (IPF) refers to a diffuse inflammatory disease of the lower respiratory tract of unknown etiology. The pathogenesis of the disease is mostly inflammation invading the alveolar wall and adjacent alveolar spaces, resulting in thickening of alveolar septa and pulmonary fibrosis. Alveolar epithelial cells and capillary endothelial cells, as well as small airways and small blood vessels, may also be affected. Its clinical features include progressive dyspnea, Velcro rales, and progressive hypoxemia. Impaired lung function is mainly restricted ventilatory dysfunction and diffusion dysfunction. The prevalence rate is about 2-5 / 100,000, and the age of onset is mostly 40-50 years old. Most of the disease courses are chronic, and those with sudden onset are rare. There is no accurate epidem...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/899A61P11/00
Inventor 李英格
Owner 内蒙古阿迪斯蒙医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products